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gingerol, provided the basis for this study in the presence 
of metabolic activation to assess the effective dose level.
Human lymphocyte culture of two healthy donors was 
carried out.[3] Later, metaphases were examined for different 
types of aberrations. For sister chromatid exchange 
analysis, bromodeoxyuridine (10 µg/ml) was added at the 
beginning of the culture.[4] Cell cycle kinetics was studied by 
the BrdU‑Harlequin technique using the replication index 
(RI) calculated by the standard formula.[5] The Student 
‘t’-test was used for statistical analysis using ‘Statistica’ 
software (StatSoft, Inc.).
In this study, cisplatin was tested in vitro in human 
lymphocytes for its toxicity potential using chromosomal 
aberrations, sister chromatid exchanges, and cell cycle 
kinetics as parameters, and it was found to be genotoxic 
only when activated metabolically in the presence of S9 mix 
[Tables 1 and 2]. This means that cisplatin can be genotoxic 
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Sir,
Cisplatin is a platinum-based chemotherapy drug used 
for treating cancers and has proved to be toxic in earlier 
studies. Cisplatin has a number of side effects that can 
limit its usage. Many agents have been shown to ameliorate 
cisplatin toxicity.[1] Genistein is an antioxidant isoflavone 
found in many plants as well as animal cells, soybeans, and 
soy products being a major source. Gingerol is the active 
constituent of fresh ginger and a proven antioxidant. 
Genistein and gingerol have been reported for their 
antigenotoxic and antimutagenic potential in cultured 
human lymphocytes.[2] The earlier reported toxicity of 
cisplatin, the antimutagenic action of genistein and 
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Table 1: Protective action of genistein and gingerol on chromosomal aberrations induced by cisplatin
Concentration Abnormal cells Chromosomal aberrations
With gaps Without gaps CAs/Cell ± SE Gaps CTB CSB CTE DIC
Cisplatin (µg/ml)
1.5 24 20 0.20 ± 0.03a 9 10 4 1 –
2.5 29 25 0.25 ± 0.04a 10 13 4 1 1
Genistein (µM)
25 3 2 0.02 ± 0.01 1 2 – – –
40 2 1 0.01 ± 0.01 1 1 – – –
Genistein+Cisplatin
25 + 1.5 17 13 0.13 ± 0.03ab 6 9 2 – –
25 + 2.5 23 19 0.19 ± 0.04ab 7 11 3 1 1
40 + 1.5 11 7 0.07 ± 0.01ab 4 5 2 – –
40 + 2.5 15 10 0.10 ± 0.02ab 5 9 1 – –
Gingerol (µM)
15 2 1 0.01 ± 0.01 1 1 – – –
25 3 2 0.02 ± 0.02 1 2 – – –
Gingerol+cisplatin
15 + 1.5 11 9 0.09 ± 0.03ab 4 6 1 – –
15 + 2.5 15 12 0.12 ± 0.04ab 5 7 3 – –
25 + 1.5 6 4 0.04 ± 0.02ab 2 3 1 – –
25 + 2.5 9 6 0.06 ± 0.03ab 3 5 1 – –
Negative control 
(DMSO, 0.5 µl/ml)
2 1 0.01 ± 0.01 1 1 – – –
Positive control (CP) 52 38 0.38 ± 0.05a 18 22 7 4 1
Untreated 3 2 0.02 ± 0.01 1 2 – – –
SE: Standard error; CTB: Chromatid break; CSB: Chromosome break; CTE: Chromatid exchange; DIC: Dicentric; DMSO: Dimethyl sulphoxide; CP: Cyclophosphamide; 
CAs: Chromosomal aberrations. aSignificant with respect to P < 0.05 for untreated. bSignificant with respect to P < 0.05 for cisplatinJournal of Young Pharmacists Vol 4 / No 2  125
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diet could protect patients undergoing chemotherapy as 
shown by studies where antioxidants were combined with 
chemotherapeutic drugs that increased growth-inhibition 
of chemotherapeutic agents on cancers.[8] Cancer cells 
and normal cells are different, which helps antioxidant 
complementary therapy protect the normal tissues 
from damage due to chemotherapeutic agents without 
compromising therapeutic effectiveness.[8] It is concluded 
that the toxicity of cisplatin could be significantly 
reduced by combining cisplatin and antioxidants during 
chemotherapy to minimize the risk of secondary tumors. 
Anticancer drugs could be developed further commercially 
from antioxidants like genistein and gingerol.
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Table 2: Protective action of genistein and gingerol 
on cell cycle kinetics and cisplatin-induced sister 
chromatid exchanges
Concentration SCEs/ 
Cell±SE
Replication 
index
Cisplatin (µg/ml)
1.5 15.34 ± 0.77a 1.25a
2.5 16.32 ± 0.81a 1.29a
Genistein (µM)
25 1.53 ± 0.22 1.67
40 1.55 ± 0.25 1.70
Genistein+cisplatin
25 + 1.5 12.67 ± 0.85ab 1.59ab
25 + 2.5 13.45 ± 0.78ab 1.47ab
40 + 1.5 10.21 ± 0.64ab 1.65ab
40 + 2.5 11.14 ± 0.61ab 1.68ab
Gingerol (µM)
15 1.45 ± 0.19 1.56
25 1.47 ± 0.21 1.59
Gingerol+cisplatin
15 + 1.5 9.34 ± 0.67ab 1.63ab
15 + 2.5 11.28 ± 0.63ab 1.58ab
25 + 1.5 12.33 ± 0.57ab 1.69ab
25 + 2.5 10.14 ± 0.55ab 1.64ab
Negative control 
(DMSO, 0.5 µl/ml)
1.45 ± 0.12 1.55
Positive control (CP) 20.73 ± 0.89a 1.33a
Untreated 1.22 ± 0.10 1.72
SE: Standard error; DMSO: Dimethyl sulphoxide; CP: Cyclophosphamide; 
SCEs: Sister chromatid exchanges. aSignificant with respect to P<0.05 for 
untreated. bSignificant with respect to P<0.05 for cisplatin
only when combined with metabolic agents during 
chemotherapy and not in the case of single treatment. 
Therefore, the combination of drugs should be carefully 
selected in order to avoid the toxicity of cisplatin. Another 
way of avoiding or reducing the toxicity of cisplatin is by 
combining it with free radical scavenging agents.[1]
Genistein and gingerol were combined with cisplatin at 
selected doses to possibly ameliorate the genotoxicity 
induced by cisplatin in the presence of a metabolic activation 
system. The two antioxidants proved to be very effective 
in reducing the genotoxicity caused by cisplatin when each 
was combined separately with cisplatin. Genistein and 
gingerol assist in preventing reactive oxygen species damage 
by scavenging free radicals that are produced by genotoxic 
agents.[6,7]
This study reveals that cisplatin has the potential to be 
genotoxic in cultured human lymphocyte chromosomes 
at 1.5 and 2.5 µg/ml (P<0.05), and the toxicity of 
cisplatin is reduced considerably, possibly because of 
the free radical scavenging activity of genistein and 
gingerol. Gingerol has greater potential to ameliorate 
genotoxicity compared to genistein. Chemotherapy leads 
to the complication of secondary cancers. Antioxidants in 
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